Associate Professor of Pharmacy Practice and Translational Research
Associate Professor of Pharmacology
University of Houston College of Pharmacy
4849 Calhoun, Room 4038
Houston, TX 77204-5039
Pharm.D. (suma cum laude), University of Houston College of Pharmacy
- Discovery of novel G-protein coupled receptor targets in the treatment of cancer
- Drug discovery for novel targets through high throughput screening and hits-to-lead optimization in the area of oncology
- Development of unique humanized cellular platforms to test the efficacy of drugs in order to predict treatment outcomes in patients
- Study of cellular signaling of proteins targeted by drugs to identify synergistic pathways and to understand mechanisms of resistance in order to design effective combination therapy in treatment of cancer
- Identification of genetic, cellular, and circulating biomarkers to predict outcome of pharmacological treatment in cancer patients
- Individualization of therapy using the information about target biology of drugs and genomics/proteomics of tumors to improve probability of achieving an objective response and improving survival
- PHARM 4301/4400 Cellular Life Sciences II
- PHAR 5297 Pharmacogenomics and Personalized Medicine
- PHAR 5403 Pharmacology II
- PHAR 5582 Advanced Therapeutics
- PHAR 5680 Oncology APPE
- Minority-serving Institution Faculty Scholar in Cancer Research Award, American Association for Cancer Research, 2016
- HOPA Basic Science and Clinical Research Literature Award, Hematology/Oncology Pharmacy Association (HOPA), 2016
- Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting Travel Award, 2015
- Provost’s Faculty Travel Award, 2014–2015
- Provost’s Faculty Travel Award, 2013–2014
- Biogen Idec Postdoctoral Fellowship Award, 2007–2009
- First place, UTHSC multidisciplinary healthcare team competition, 2004
- Facts and Comparison, Award of Excellence in Clinical Communications, 2004
- Young Investigator Award, Society of Experimental Biology and Medicine, 2004
- Graduate Student Travel Award, Experimental Biology, 2004
- Sigma Xi Graduate Student Research Award, 2004
- Fellow, American Foundation for Pharmaceutical Education, 2003–2004
- Perrin Lokhandwala Pharm.D.-Ph.D. Scholarship, 2003–2004
- Sigma Xi Graduate Student Poster Award, 2003
- Makhtoob Alam Graduate Student Scholarship, 2002–2003
- Rho Chi honor for exemplary performance, 2000
- Dean’s Honor List and Scholarship, University of Houston, 1998–2002
Hwang GS, Paranjpe R, Opsomer C, Lu K, Abajue U, Abughosh S, Zaghloul H, Trivedi MV. Oral endocrine therapy agent, race/ethnicity, and time on therapy predict adherence in breast cancer patients in a large academic institution. Clin Breast Cancer. 13:S1526-8209(20):30148-8, 2020.
Buono G, Crispo A, Giuliano M, De Angelis C, Schettini F, Forestieri V, Lauria R, De Laurentiis M, De Placido P, Rea CG, Pacilio C, Esposito E, Grimaldi M, Nocerino F, Porciello G, Giudice A, Amore A, Minopoli A, Botti G, De Placido S, Trivedi MV, Arpino G. Metabolic Syndrome and Early Stage Breast Cancer Outcome: Results From a Prospective Observational Study. Breast Cancer Res Treat. 182(2):401-409, 2020.
De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 Feb 1;26(3):738-745. doi: 10.1158/1078-0432.CCR-19-1402. Epub 2019 Oct 25.
Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, Kumar T, Abdulkareem NM, Mao S, Nardone A, Rimawi M, Osborne CK, Lewis MT, Levine H, Zhang B, Schiff R, Giuliano M, Trivedi MV. A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. J Clin Med. 2019 Oct 24;8(11). pii: E1772. doi: 10.3390/jcm8111772.
Hoang JM, Upadhyay N, Dike DN, Lee J, Johnson ML, Cleeland CS, Mendoza T, Chen H, Trivedi MV. Patient-reported outcomes in light of supportive medications in treatment-naive lung cancer patients. Support Care Cancer. 2020 Apr;28(4):1809-1816. doi: 10.1007/s00520-019-05004-8. Epub 2019 Jul 23.
Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R. The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019;120(3):331-9. Epub 2018/12/18. doi: 10.1038/s41416-018-0354-9. PubMed PMID: 30555156; PMCID: PMC6353941.
Paranjpe R, John G, Trivedi M, Abughosh S. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019;174(2):297-305. Epub 2018/12/14. doi: 10.1007/s10549-018-05073-z. PubMed PMID: 30523459.
Ramirez AB, Bhat R, Sahay D, De Angelis C, Thangavel H, Hedayatpour S, Dobrolecki LE, Nardone A, Giuliano M, Nagi C, Rimawi M, Osborne CK, Lewis MT, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12;19(1):220. doi: 10.1186/s12885-019-5382-1. PMID: 30871481
Paranjpe R, Basatneh D, Tao G, De Angelis C, Noormohammed S, Ekinci E, Abughosh S, Ghose R, Trivedi MV. Neratinib in HER2-Positive Breast Cancer Patients. Ann Pharmacother. 2019 Jun;53(6):612-620. doi: 10.1177/1060028018824088. Epub 2019 Jan 4. PMID: 30607980
Rascon K, Flajc G, De Angelis C, Liu X, Trivedi MV, Ekinci E. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. Ann Pharmacother. 2019 May;53(5):501-509. doi: 10.1177/1060028018817904. Epub 2018 Dec 7. PMID: 30522347
Montanari M, Carbone MR, Coppola L, Giuliano M, Arpino G, Lauria R, Nardone A, Leccia F, Trivedi MV, Garbi C, Bianco R, Avvedimento EV, De Placido S, Veneziani BM. Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. Mol Cancer Res. 2019 Feb;17(2):628-641. doi: 10.1158/1541-7786.MCR-17-0324. Epub 2018 Sep 21. PMID: 30242055
Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R, Trivedi MV. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul;170(2):279-292. doi: 10.1007/s10549-018-4751-9. Epub 2018 Mar 24. PMID: 29574636
Giuliano M, Shaikh A, Lo HC, Arpino G, De Placido S, Zhang XH, Cristofanilli M, Schiff R, Trivedi MV. Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Res. 2018 Feb 15;78(4):845-852. doi: 10.1158/0008-5472.CAN-17-2748. Epub 2018 Feb 2. PMID: 29437766
Ekinci E, Nathoo S, Korattyil T, Vadhariya A, Zaghloul HA, Niravath PA, Abughosh SM, Trivedi MV. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 Jun;12(3):348-356. doi: 10.1007/s11764-017-0674-4. Epub 2018 Feb 2. Review. PMID: 29396760
Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G, Giuliano M. PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? Breast Care (Basel). 2017 Oct;12(5):290-294. doi: 10.1159/000481657. Epub 2017 Oct 19. Review. PMID: 29234247
Niravath P, Bhat R, Al-Ameri M, AlRawi A, Foreman C, Trivedi MV. Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy. Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.330. PMID: 28805983
Hwang GS, Bhat R, Crutchley RD, Trivedi MV. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J. 2018 Apr;18(2):201-208. doi: 10.1038/tpj.2017.36. Epub 2017 Aug 1. Review. PMID: 28762370
Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, Tsimelzon A, Gutierrez C, Huang S, Edwards DP, Trivedi MV, Rimawi MF, Lopez-Terrada D, Hilsenbeck SG, Gray JW, Brown M, Osborne CK, Schiff R. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci. 25;113(43):E6600-E6609, 2016.
Sulaica E, Han T, Wang W, Bhat R, Trivedi MV, Niravath P. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2016 Jun;157(2):203-10. doi: 10.1007/s10549-016-3827-7. Epub 2016 May 13. Review. PMID: 27178335
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10. PMID: 26965145
Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV. Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. Nutr Clin Pract. 2016 Apr;31(2):171-9. doi: 10.1177/0884533615611857. Epub 2015 Oct 27.
Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV*. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: A meta-analysis. Breast Cancer Res and Treat. 153(3):591-597, 2015.
Nardone A, De Angelis C, Trivedi MV, Osborne CK, Schiff R. The changing role of ER in endocrine resistance. The Breast. 24(Supp2):S60-S66, 2015.
Giuliano M, Wang YC, Gutierrez C, Rimawi MF, Chang JC, Wang T, Hilsenbeck SG, Trivedi MV, Chamness GC, Osborne CK, Schiff R. Upregulation of estrogen receptor signaling in HER2-positive breast cancer patients treated with neoadjuvant lapatinib: a translational study. Clin Cancer Res. 21(17):3995-4003, 2015.
Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV*. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 17(1):3, 2015.
Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19(23):6389-6397, 2013.
Garcia S, Atkins J, Falchook G, Tsimberidou A, Hong D, Trivedi MV*, Kurzrock R. Transient Severe Hyperbilirubinemia After Hepatic Arterial Infusion of Oxaliplatin in Patients with Liver Metastases. Cancer Chemotherapy Pharmacology. 72(6):1265-1271, 2013.
Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care. 8(4):256-262, 2013. (Invited review)
Parma J, Pavlick A, Schiff R, Osborne CK, Chang JC, Rimawi M, Trivedi MV*. Incidence of acneiform rash does not predict treatment response to lapatinib in breast cancer. Pharmacotherapy. 33(10):1126-1129, 2013.
Choi S, Rajan S, Trivedi MV*. The incidence of tumor cell contamination of the peripheral blood stem cells: A meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematologica. 31(3):133-140, 2013.
Giuliano M, Trivedi MV, Schiff R. Die and let live: harnessing BikDD to combat breast cancer stem cells. Breast Cancer Research. 14(3):310, 2012.
Preston JN, Trivedi MV. Eribulin (Halaven): a novel cytotoxic chemotherapy agent. Ann Pharmacother. 2012 Jun;46(6):802-11.
Nangia JR, Ma JD, Nguyen CM, Mendes MA, Trivedi, MV. Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr;12(4):491-501.
Ikediobi O, Nangia J, Trivedi MV. Chapter 13. Pharmacogenomics in Oncology. Pharmacogenomics: An Introduction and Clinical Perspective: Volume 1. (pp. 173-190). McGraw-Hill, Columbus, OH, 2012.
Sahay D, Ramirez AB, Bhat RR, Dobrolecki LE, Nardone A, Lewis MT, Osborne CK, Rimawi M, Stilwell JL, Kaldjian EP, Schiff R, Trivedi MV. CTCs and CTC clusters in breast cancer patient-derived xenograft models. Cancer Research. In print, Abstract nr 3969, 2016.
Sahay D, Bhat RR, Yadav P, Christiny P, Rimawi M, Osborne CK, Schiff R, Trivedi MV. Role of GPR110 on tumorigenesis and metastasis in HER2+ breast cancer in the context of anti-HER2 drug resistance. In print, Abstract nr 319, 2016.
Han T, Sulaica E, Niravath P, Trivedi MV. Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Presented at Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, 2016.
Hwang G, Trivedi MV. Systematic Review To Evaluate The Impact Of CYP2D6 Genotype-Phenotype On Endoxifen Concentrations And Breast Cancer Outcomes. Presented at Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, 2016.
Bhat R, Yadav P, Christiny P, Schiff R, Trivedi MV. Novel G protein-coupled receptor targets in HER2+ breast cancer. Presented at AACR Annual Meeting, Cancer Research. 75(15 Suppl):Abstract nr 3573, 2015.
Do T, Niravath P, Trivedi MV. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the adjuvant docetaxel and cyclophosphamide in patients with early-stage breast cancer: A meta-analysis. J Clin Oncol., 33(15 Suppl):e20707, 2015.
Do T, Niravath P, Trivedi MV. Risk of Febrile Neutropenia with Adjuvant Docetaxel and Cyclophosphamide Therapy in Patients with Early-Stage Breast Cancer. Presented at Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting, 2015.
Fetea A, Trivedi MV. Efficacy and Safety of Epidermal Growth Factor Receptor-targeted Therapy in Breast Cancer. Presented at HOPA Annual Meeting, 2015.
Giuliano M, Herrera S, Christiny P, Shaw C, Creighton CJ, Mitchell T, Bhat R, Zhang X, Mao S, Dobrolecki LE, Al-rawi A, Chen F, Veneziani BM, Zhang XH, Hilsenbeck SG, Contreras A, Gutierrez C, Jeselsohn RM, Rimawi MF, Osborne CK, Lewis MT, Schiff R, Trivedi MV. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. San Antonio Breast Cancer Symposium, 2014.
Bhat R, Yadav P, Christiny P, Nanda S, Osborne CK, Schiff R, Trivedi MV. Expression and function of GPCRs in HER2+ breast cancer. Keystone Symposium on G protein-Coupled Receptors: Structural Dynamics and Functional Implications, 2014.
Bhat R, Yadav P, Yadav V, Al-rawi A, Christiny P, Nanda S, Osborne CK, Narkar V, Schiff R, Trivedi MV. Identification of novel GPCR targets in HER2+ breast cancer. American Association of Colleges of Pharmacy, 2014.
Trivedi MV, Bhat R, Yadav V, Yadav P, Al-rawi A, Christiny P, Nanda S, Giuliano M, Creighton C, Osborne CK, Narkar VA, Schiff R. GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells. San Antonio Breast Cancer Symposium, 2013.
Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Gastroenterology. 144(5): Supplement 1, Abstract Su1015, 2013.
Huynh NM, Trivedi MV. Incidence of Skin Toxicity and Diarrhea Associated with Receptor Tyrosine Kinase Inhibitors Treatment in Cancer Patients: A Systematic Review. Hematology Oncology Pharmcy Association (HOPA) Annual Meeting, 2013. [Nhu-Mai Huynh was the recipient of HOPA student travel award].
Garcia SS, Atkins JT, Falchook GS, Tsimberidou AM, Hong DS, Trivedi MV, Kurzrock, R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Hematology Oncology Pharmacy Association (HOPA) Annual Meeting, 2013. [Selected for Encore Abstract].
Yadav P, Bhat R, Chayanam, S, Christiny P, Nanda, S, Hu, Huizhong, Creighton C, Osborne CK, Schiff R, Trivedi MV. Identification of novel G-protein coupled receptor targets in HER2-positive breast cancer. Cancer Research. 72(24): Supplement 3, Abstract P4-06-02, 2012.
Giuliano M, Christiny PI, Zhang X, Mao S, Contreras A, Lewis MT, Rimawi MF, Osborne CK, Schiff R, and Trivedi MV. Identification of Triple-Negative Primary Breast Cancer Xenograft Models with High Numbers of Circulating and Disseminated Tumor Cells. Cancer Research. 71(24):445s, 2011.
Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Hilsenbeck SG, Healy N, Mazumdar A, Trivedi MV, Jeselsohn R, He HH, Fu X, Gutierrez C, Brown M, Brown PH, Osborne CK, and Schiff R. AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer. Cancer Research. 71(24):429s, 2011.
Parma JM, Pavlick AC, Chang JCN, Rimawi MF, Trivedi MV. Acneiform rash does not predict response to neoadjuvant lapatinib monotherapy in breast cancer patients. Pharmacotherapy 31(10e): 433e, 2011.
Choi S, Trivedi MV. Effects of mobilization regimens on the incidence of tumor cell contamination of the hematopoietic stem cells in breast cancer patients undergoing peripheral blood stem cell transplantation. Pharmacotherapy 31(10e): 432e, 2011.
Parma JM, Pavlick, AC, Chang JCN, Rimawi MF, Trivedi M. Does incidence of rash predict treatment response to lapatanib in breast cancer? J Clin Oncol. 29 suppl abstr:e11127, 2011.
Trivedi, M., Corringham, S., Martinez, S., Ball E.D., Medley, K. Review and revision of the clinical practice of G-CSF treatment in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation at UCSD. Pharmacotherapy, 29:65e, 2009.
Tran, T., Lau, R., Barnachea, L., Batarse, B., Shen, F., Gonzales, J., Wilson, S., Tang, E., Trivedi, M. Assessment of Complementary and Alternative Medicine Utilization in Cancer Patients at Moores UCSD Cancer Center and Analysis of Drug Interactions. Journal of Oncology Pharmacy Practice, Trainee abstracts program book, 2009.
Lau, R., Tran, T., Batarse, B., Shen, F., Gonzales, J., Wilson, S., Barnachea, L., Tang, E., Trivedi, M. Assessment of Complementary and Alternative Medicine Utilization in Cancer Patients at Moores UCSD Cancer Center. Pharmacotherapy, 29:104e, 2009.
Trivedi, M., Corringham, S., Martinez, S., Medley, K., Ball E.D. Independent and interdependent influence of number of CD34+ cells and use of G-CSF on outcomes in autologous PBSCT patients. Blood, 112:4319, 2008.
Trivedi, M., Li, L., Fletcher, L., Wu, X., Yang, Y., Shankley, N. Utilization of G1E-ER4 cells to study hemoglobin synthesis. FASEB J, 21:lb393, 2007.
Lokhandwala, M.F., Marwaha, A., Trivedi, M., Banday, A.A.: Oxidative Stress and renal dopamine D1 receptor function in experimental diabetes. Clin Exp Hypertension, 29:223, 2007.
Updates from San Antonio Breast Cancer Symposium. HOPA Emerging Issues in Oncology Webinar series, 03/2016.
Pharmacogenomic: advancing personalized medicine. MedAssets Southwest Regional Pharmacy Meeting, 10/2015.
Supportive Care During Cancer Treatment: The Pharmacist’s Role. Texas Pharmacy Association Conference & Expo, 7/2015.
Breast cancer research: time for action is now. Kappa Epsilon Silver Jubilee event, Breast Cancer Awareness Dinner, University of Houston, 10/2014.
Identification of novel GPCR targets in HER2+ breast cancer. American Association of Colleges of Pharmacy, 7/2014.
Breast cancer: through the glasses of a pharmacist and a researcher. Kappa Epsilon Silver Jubilee event, Breast Cancer Awareness Dinner, University of Houston, 10/2013.
Circulating tumor cells in breast cancer: beyond clinical prognosis. NCI-ICBP Center for Modeling Cancer Development Seminar, The Methodist Hospital Research Institute, 2011.
- American Association for Cancer Research (AACR)
- American Society of Clinical Oncology (ASCO)
- Texas Society of Clinical Oncology (TxSCO)
- American College of Clinical Pharmacy (ACCP)
- Hematology Oncology Pharmacy Association (HOPA)
Editorial and Service Appointments
- Manuscript Reviewer: Breast Cancer Research (2014–present); PLoS One (2012–present); Bone Marrow Transplantation (2009–present); Clinical and Experimental Hypertension (2004–2011)
- Grant Reviewer: DoD CDMRP BCRP Scientific reviewer (2015-present); ACCP Junior Investigator Award Grant Review Committee (2015-present); Laura W. Bush Institute for Women's Health (2013-present)
- Member, Hematology/Oncology Pharmacy Association (HOPA) Research Committee (2015-2017); Member, HOPA Research Abstract Committee (2013-2014); Member, HOPA Publication Committee (2012–2013); Trainee Member, HOPA Research Committee (2008-2009); Trainee Member, American College of Clinical Pharmacy Focus Session (2007-2008); Member, UCSD Moores Cancer Center Protocol Review & Monitoring Committee (2007-2009)